Your session is about to expire
← Back to Search
Radiation Therapy + Atezolizumab for Small Cell Lung Cancer
Study Summary
This trial will compare the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab (a monoclonal antibody) versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My small cell lung cancer is confirmed and has spread.I have had whole brain radiation for my brain metastases.My cancer stage fits the study requirements based on tests and scans.My autoimmune disease has been inactive for over 3 years or is under stable treatment.My HIV is stable and I am on effective treatment.My blood, liver, and kidney functions are all within normal ranges.I do not have recent heart issues or significant lung disease.I have a condition that weakens my immune system or COPD needing long-term oral steroids.Women who could become pregnant must have a negative pregnancy test.My cancer is a type called extensive stage small cell lung cancer.My cancer did not worsen after 4-6 cycles of specific chemotherapy and immunotherapy.My cancer has spread to my liver with 3 or fewer spots and is not getting worse.I can take care of myself and am up and about more than half of my waking hours.I do not have severe illnesses like active TB or serious liver disease.I can receive radiation for symptoms caused by cancer spread.I have had an organ transplant or lung inflammation from immunotherapy.My cancer can be measured, has 3 or fewer liver spots, and isn't getting worse.I do not have another cancer that could affect this treatment's safety or results.My cancer has spread to my liver or heart, or I have more than 10 areas where cancer has spread.I have had radiation therapy in my chest area that overlapped.
- Group 1: Arm II (atezolizumab, radiation therapy)
- Group 2: Arm I (atezolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this study mainly taking place in North American hospitals?
"Presently, this clinical trial is looking for patients from a pool of 100 different enrolment sites. Some of these sites are located in Danville, Des Moines, and Brighton. There are also many other sites which are closer to where potential patients might live. This is to reduce the amount of travel required, should somebody choose to enroll in the trial."
Have other companies conducted similar research projects?
"Since its inception in 2008, Radiation Therapy has been the focus of many studies. The first was sponsored by Genentech, Inc and was published in 2008. After the success of the initial trial, which recruited 720 participants, Radiation Therapy received Phase 2 approval. Currently, there are 361 active trials being conducted in 1668 cities and 74 countries."
What types of cancer does Radiation Therapy typically target?
"Radiation therapy can be used to target small cell lung cancer specifically, but it is also a viable treatment option for non-small cell lung carcinoma and postoperative patients."
What other scientific papers have been published on the topic of Radiation Therapy?
"Radiation therapy was first studied in 2008 at National Cheng Kung Uni Hospital. There have been a total of 181 completed trials since then. Danville, Pennsylvania is currently conducting a significant number of the 361 live clinical trials."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- University of Cincinnati Cancer Center-UC Medical Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger